Orbsen in fundraising efforts to drive Phase II and potentially Phase IIb mesenchymal stromal cell therapy plans; Phase IIb start likely in mid to late 2021, exec says
Orbsen in fundraising efforts to drive Phase II and potentially Phase IIb mesenchymal stromal cell therapy plans; Phase IIb start likely in mid to late 2021, exec says Published Date:20 Apr 2020 Phase IIb could include COVID-19 focus depending on results Orbsen in talks with and open to CMOs to manage downstream manufacturing [...]